Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.55 USD
-0.03 (-5.09%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.55 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNXP 0.55 -0.03(-5.09%)
Will TNXP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TNXP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TNXP
Tonix Pharma gains on FDA fast track tag for pain therapy
Tonix Pharmaceuticals granted Fast Track Designation by FDA for Tonmya
Tonix price target raised to $11 from $6 at Alliance Global Partners
Tonix Pharmaceuticals to file NDA for Tonmya in 2H24
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025